Mirati Therapeutics, Inc. (MRTX) Social Stream
Featured Post From StockTwits About MRTX
$KDMN, pegged at $500m annual peak sales and significant improvement in quality of life for chronic GVHD patients (meaning payers will provide coverage).Jasooon, published July 17, 2021
"Patients receiving [belumosudil] reported significant improvements in chronic GVHD symptoms, showing that not only did treatment result in organ responses, but it also made people feel better. This is so important for a chronic disease with a high symptom burden," Stephanie Lee, MD, MPH, professor at the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, and research director of the Long-Term Follow-Up Program at Fred Hutchinson, noted in the release.
$MRTX $GTHX $KPTI